Loading...
XJPX4202
Market cap2.44bUSD
Dec 26, Last price  
1,392.00JPY
1D
1.53%
1Q
0.98%
Jan 2017
7.91%
Name

Daicel Corp

Chart & Performance

D1W1MN
XJPX:4202 chart
P/E
6.88
P/S
0.69
EPS
202.21
Div Yield, %
3.35%
Shrs. gr., 5y
-3.34%
Rev. gr., 5y
3.72%
Revenues
558.06b
+3.72%
306,335,000,000335,520,000,000381,422,000,000416,989,000,000377,979,000,000320,243,000,000353,684,000,000341,942,000,000358,513,000,000413,786,000,000443,775,000,000449,878,000,000440,061,000,000462,956,000,000464,859,000,000412,826,000,000393,568,000,000467,937,000,000538,026,000,000558,056,000,000
Net income
55.83b
+37.24%
10,844,000,00014,220,000,00017,438,000,00013,675,000,0001,296,000,00011,069,000,00016,802,000,00011,827,000,00015,372,000,00022,843,000,00031,252,000,00040,313,000,00043,198,000,00037,062,000,00035,301,000,0004,978,000,00019,713,000,00031,254,000,00040,682,000,00055,834,000,000
CFO
76.73b
+185.80%
41,683,000,00032,780,000,00025,534,000,00049,275,000,00040,165,000,00066,445,000,00053,428,000,00034,000,000,00044,480,000,00044,777,000,00057,412,000,00065,419,000,00086,168,000,00066,888,000,00058,523,000,00057,193,000,00057,869,000,00042,993,000,00026,847,000,00076,729,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 03, 2025

Profile

Daicel Corporation engages in the medical/healthcare, smart, safety, materials, engineering plastics, and other businesses in Japan, China, and internationally. The company offers 1,3-Butylene glycol and polyglycerin for cosmetics; chiral and achiral columns/stationary phases, analytical tools, analytical/purification/synthesis/formulation services, chiral and bio reagents, analytical standards, and DNA and RNA-based probes; triacetylcellulose, high performance film, solvent for electronic materials, polymer for resist, semiconductor process cleaning agent, optical parts and lens unit, silver nanoparticle ink, and organic semiconductor devices; and inflators, pyro-fuse, and safety device for non-mobility products; and acetic acid and derivatives, cellulose acetate, acetate tow, cycloaliphatic epoxies, caprolactone, ketene derivatives, and alkylamines. It also provides ceramide derived from konjac root, equol derived from soybeans, ß-cryptoxanthin derived from citrus unshiu, and lactobionic acid derived from milk; DiSPERZiSTA, a dispersible filler for dietary supplement tablet; and MOiSTCARM, a make granules easy to swallow. In addition, the company offers engineering plastics and plastic compound products, high performance polymer, functional sheets, formed trays, and packaging films; water treatment systems and diffusers, such as UF membrane modules, ultra-fine bubble membrane diffusers, and E mizu showers. Its products are used in transportation, electronics, medical care, personal care, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and headquartered in Osaka, Japan.
URL
https://www.daicel.com/
IPO date
May 16, 1949
Employees
11,207
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
558,056,000
3.72%
538,026,000
14.98%
467,937,000
18.90%
Cost of revenue
496,770,000
491,749,000
418,313,000
Unusual Expense (Income)
NOPBT
61,286,000
46,277,000
49,624,000
NOPBT Margin
10.98%
8.60%
10.60%
Operating Taxes
19,487,000
13,326,000
14,229,000
Tax Rate
31.80%
28.80%
28.67%
NOPAT
41,799,000
32,951,000
35,395,000
Net income
55,834,000
37.24%
40,682,000
30.17%
31,254,000
58.55%
Dividends
(12,859,000)
(10,651,000)
(9,645,000)
Dividend yield
3.01%
3.64%
3.93%
Proceeds from repurchase of equity
(15,000,000)
46,519,000
9,380,000
BB yield
3.51%
-15.88%
-3.83%
Debt
Debt current
85,049,000
109,009,000
44,473,000
Long-term debt
221,141,000
211,766,000
238,146,000
Deferred revenue
8,000
6,098,000
9,144,000
Other long-term liabilities
13,889,000
5,002,000
3,912,000
Net debt
143,147,000
137,704,000
95,886,000
Cash flow
Cash from operating activities
76,729,000
26,847,000
42,993,000
CAPEX
(69,208,000)
(51,923,000)
(47,471,000)
Cash from investing activities
(55,374,000)
(44,093,000)
(46,528,000)
Cash from financing activities
(52,373,000)
19,956,000
(5,452,000)
FCF
(29,001,000)
(33,982,000)
(14,573,000)
Balance
Cash
73,183,000
93,840,000
90,528,000
Long term investments
89,860,000
89,231,000
96,205,000
Excess cash
135,140,200
156,169,700
163,336,150
Stockholders' equity
390,753,000
551,237,000
490,317,000
Invested Capital
556,596,800
477,852,300
404,234,850
ROIC
8.08%
7.47%
9.34%
ROCE
8.57%
7.14%
8.50%
EV
Common stock shares outstanding
282,617
292,957
300,115
Price
1,514.00
51.40%
1,000.00
22.40%
817.00
-4.11%
Market cap
427,882,118
46.06%
292,957,000
19.48%
245,193,955
-4.85%
EV
586,993,118
671,107,000
553,306,955
EBITDA
94,989,000
77,852,000
77,819,000
EV/EBITDA
6.18
8.62
7.11
Interest
1,668,000
1,432,000
1,361,000
Interest/NOPBT
2.72%
3.09%
2.74%